Over the course of a day, the average person will walk three miles. Over the course of three days, Dearric Winchester will run more than 72 times that average during the 11th annual Cascade Lakes Relay (CLR) in beautiful Central Oregon. Armed with months of training and a support van full of family and friends, Winchester will battle dramatic temperature
Professor Lyn Griffiths Executive Director, Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia Conclusion: Dr. Griffiths has tested a quicker, more cost-effective genetic identification methodology, called Next Generation Sequencing(NGS). The utilization of the NGS methodology has proven successful in identifying individuals with the FHM mutation, and has proven to be 100% consistent with the older (Sanger) methodology. The
Learn more about migraine disease and what to do about it.
AMD begins their podcast series “Shades of Migraine”
The Association of Migraine Disorders raised $14,000 for research at its third annual Mad Hatter Party, held June 23 at the Squantum Association in East Providence. Read More
Full Project Title: A Prospective Randomized Cross-over Trial of Nortiptyline and Topiramatenin the initial Treatment of Vestibular Migraine Principal Investigator: Anthony Mikulec MD, MPH Professor, Chief, Otology and Nuerotology, Saint Louis University School of Medicine Update: Despite the high number of migraine patients in our clinics, it continues to be more challenging than anticipated to identify patients who have not previously
As an ardent follower of the recent advances in the understanding and treatment of migraine disorders I am impressed with the great strides made over the last 24 months. It is remarkable that since the 1990s and the introduction of triptans, so much significant work in both prevention and treatment is now coming to fruition. So why now? What forces
Traumatic Brain Injury and Migraines: Civilian and Military Implications Consideration of this subject brings us to the intersection of some of the most critical issues challenging the migraine treatment community. With Memorial Day fading in the rear view mirror, we at AMD began to reflect on a number of these issues and thought looking at Traumatic Brain Injury (TBI) may
“There is no condition of such magnitude that is as shrouded in myth, misinformation, and mistreatment as is this condition [Migraine], and there are few conditions which are as disabling during the acute attack.” -Dr. Joel R. Saper, M.D., F.A.C.P., Director, Michigan Head-Pain & Neurological Institute A young science such as the one attempting to rid the world of migraine
1. What is a migraine, and how can you know you’re having one? A traditional migraine headache is an intense, throbbing pain that most people associate with the top of their heads. Those who suffer from migraines, also known as migraineurs, know a headache is coming on when they experience distortions of their vision or when their headache is accompanied by
Principal investigator: Maggie Waung, MD University of California, San Francisco Update: The main hypothesis of this project is that the metabotropic glutamate receptors are involved in trigeminovascular pain processing. This study is running under budget but, due to change in animal model, it has been extended for an additional year (2017).
Foreword for The Migraine Relief Diet is written by Frederick Godley, III, MD, FACS, President of the Association of Migraine Disorders and Michael Teixido, MD, Vice President of the Association of Migraine Disorders (excerpted from “The Migraine Relief Diet” by Tara Spencer, (c) Callisto Media/Althea Press), available here at Amazon.com in both softcover and kindle editions) Many people aren’t aware of how common
This is an annual event, organized by the nonprofit Alliance for Headache Disorders Advocacy (AHDA), to advocate on behalf of Americans with disabling headache disorders. This is primarily a grassroots advocacy for increased funding of headache research. Its founder and thought-leader is Robert E. Shapiro, MD, PhD and its president is William B. Young, MD. AHDA is supported by a confederation
Our first annual scientific and educational advisory board meeting, on October 23rd, was full of invigorating discussion and a wealth of great ideas. It underscores how essential the word “collaborate” is within the goals of our Mission. I am very grateful, for every member shared their time and expertise with a generosity of spirit in the common goal: assisting patients
Dolor Technologies has developed for the U.S. its patented, advanced drug delivery catheter, SphenoCath™. SphenoCath is a single-use, disposable catheter that delivers lidocaine via the nasal passages to a hard-to-reach ganglion (SPG) located at the back of the nose without use of painful needles, sprays, swabs or sedation, which is a real advantage. When used as prescribed, SpenoCath saturates and prolongs the medication
“Here, for the first time ever, is a specific treatment for migraine prevention,” “It’s an enormous step forward.” – Peter Goadsby, MD, Chief of the University of California, San Francisco Headache Center, and Chairman of the American Headache Society Finally, after decades of waiting real hope is on the horizon in the form of a small molecule called a Calcitonin
Healthcare is expensive. We all know this. Even under the best of circumstances, a generally healthy person, can dedicate a large portion of income in service of insurance premiums, deductibles, co-insurance, co-pays, and medications to name a few “usual ” expenses. The stakes, and expenses, get much higher when you introduce a chronic disabling illness, like migraine. We can start
36 Million Migraineurs in the US alone may think they have a built in reason for avoiding sexual relations, but it’s not always a headache. A study from the University of Munster in Germany, http://www.ncbi.nlm.nih.gov/pubmed/23430983 with a large sample (about 400 people ) uncovered some interesting results. They surveyed both migraineurs and those that suffered cluster headaches. Our Teutonic Colleagues distributed a
The past year shapes up to be a particularly productive one in terms of research, and in some cases product roll-out, for potential relief from migraines and related disorders. Oral triptans have been the first line of treatment for migraines for the past several decades, with precious little to look forward to, until recently. Why the new interest from Big
How is it possible that such a devastating illness in all its expressions could not have far-reaching, negative effects in all relationship areas of a migraineurs life? It’s not, of course. Only recently have we begun to see research that looks at subjects like family burden and the disruption chronic migraine causes in the lives of sufferers. Very few of
The Migraine Research Foundation (MRF) and the Association of Migraine Disorders (AMD) announce the opening of a joint Request for Proposals for migraine research grants. MRF is committed to discovering the causes, improving the treatments, and finding a cure, and AMD stimulates increased research specifically in the area of migraine disorders. We’re looking for projects that will help sufferers by